Report Detail
Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4685246 |
- 12 March, 2026 |
- Global |
- 83 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market size was valued at US$ 158 million in 2025 and is forecast to a readjusted size of US$ 289 million by 2032 with a CAGR of 8.7% during review period.
In 2025, global Anti-ANGPTL3 Antibody Lipid-lowering Drugs production reached approximately 19.19 K Units, with an average global market price of around 7988 USD per Unit.
Anti-ANGPTL3 Antibody Lipid-lowering Drugs is a monoclonal antibody designed to bind and inhibit angiopoietin-like protein 3 (ANGPTL3), a circulating liver-derived protein that regulates lipid metabolism by suppressing lipoprotein lipase (and related pathways). By neutralizing ANGPTL3’s activity, these antibodies aim to increase triglyceride-rich lipoprotein clearance and reduce atherogenic lipids (such as LDL cholesterol and triglycerides), and are used or developed for treating severe dyslipidemias and reducing cardiovascular risk.Evolocumab is the only marketed Anti-ANGPTL3 Antibody Lipid-lowering Drugs globally. It has been approved by the US FDA for the treatment of homozygous familial hypercholesterolemia (HoFH).
Anti-ANGPTL3 antibodies are compelling because they target a well-defined, liver-driven control point in lipid metabolism that can address a persistent industry pain point: a subset of patients remain at high cardiovascular risk despite today’s standard lipid-lowering options, either because of severe inherited dyslipidemias, mixed lipid abnormalities, intolerance, or residual risk that is not fully captured by LDL-centric approaches. By neutralizing ANGPTL3, these antibodies can reduce atherogenic lipoprotein burden through mechanisms that are complementary to statins and PCSK9 inhibitors, offering clinicians a differentiated tool when conventional pathways plateau and enabling a precision-medicine narrative for complex lipid phenotypes where triglycerides, remnants, and broader dyslipidemia matter. The category is being propelled by structural drivers that have reshaped cardiometabolic drug development: rising global prevalence of obesity and diabetes, stronger emphasis on preventing costly downstream events, increasing sophistication in genetic and biomarker-enabled patient identification, and growing confidence among payers and health systems in high-value biologics that demonstrate meaningful risk reduction in well-defined populations. Anti-ANGPTL3 antibodies have credible market runway as evidence and clinical experience mature, positioning expands from rare and refractory patients toward broader high-risk segments where unmet need remains, and combination strategies with established lipid therapies become more clearly standardized, making the class an attractive long-term opportunity within the evolving cardiometabolic landscape without relying on exaggerated claims.
The upstream raw materials for Anti-ANGPTL3 Antibody Lipid-lowering Drugs mainly include ANGPTL3 recombinant protein, CHO cells, etc. Typical raw material suppliers include Thermo Fisher, Merck, Pall, etc. The downstream application is mainly for people with high blood lipids.
The production capacity of Anti-ANGPTL3 Antibody Lipid-lowering Drugs production lines varies greatly depending on the type of drug molecule, process complexity, equipment scale, and production mode. The industry gross profit margin is usually in the range of 60%-80%.
This report is a detailed and comprehensive analysis for global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-ANGPTL3 Antibody Lipid-lowering Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-ANGPTL3 Antibody Lipid-lowering Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron, Eli Lilly, Jiangsu Hengrui Medicine, Cspc Holdings, Suzhou Ribo Life Science, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Anti-ANGPTL3 Antibody Lipid-lowering Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal Antibody
Polyclonal Antibody
Others
Market segment by Mechanism of Action
Direct Neutralization
Indirect Inhibition
Market segment by Route of Administration
Intravenous Injection
Subcutaneous Injection
Market segment by Application
Homozygous Familial Hypercholesterolaemia (HoFH)
Others
Major players covered
Regeneron
Eli Lilly
Jiangsu Hengrui Medicine
Cspc Holdings
Suzhou Ribo Life Science
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anti-ANGPTL3 Antibody Lipid-lowering Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-ANGPTL3 Antibody Lipid-lowering Drugs, with price, sales quantity, revenue, and global market share of Anti-ANGPTL3 Antibody Lipid-lowering Drugs from 2021 to 2026.
Chapter 3, the Anti-ANGPTL3 Antibody Lipid-lowering Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-ANGPTL3 Antibody Lipid-lowering Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Anti-ANGPTL3 Antibody Lipid-lowering Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-ANGPTL3 Antibody Lipid-lowering Drugs.
Chapter 14 and 15, to describe Anti-ANGPTL3 Antibody Lipid-lowering Drugs sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Monoclonal Antibody
- 1.3.3 Polyclonal Antibody
- 1.3.4 Others
- 1.4 Market Analysis by Mechanism of Action
- 1.4.1 Overview: Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Mechanism of Action: 2021 Versus 2025 Versus 2032
- 1.4.2 Direct Neutralization
- 1.4.3 Indirect Inhibition
- 1.5 Market Analysis by Route of Administration
- 1.5.1 Overview: Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
- 1.5.2 Intravenous Injection
- 1.5.3 Subcutaneous Injection
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Homozygous Familial Hypercholesterolaemia (HoFH)
- 1.6.3 Others
- 1.7 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Size & Forecast
- 1.7.1 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity (2021-2032)
- 1.7.3 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Regeneron
- 2.1.1 Regeneron Details
- 2.1.2 Regeneron Major Business
- 2.1.3 Regeneron Anti-ANGPTL3 Antibody Lipid-lowering Drugs Product and Services
- 2.1.4 Regeneron Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Regeneron Recent Developments/Updates
- 2.2 Eli Lilly
- 2.2.1 Eli Lilly Details
- 2.2.2 Eli Lilly Major Business
- 2.2.3 Eli Lilly Anti-ANGPTL3 Antibody Lipid-lowering Drugs Product and Services
- 2.2.4 Eli Lilly Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Eli Lilly Recent Developments/Updates
- 2.3 Jiangsu Hengrui Medicine
- 2.3.1 Jiangsu Hengrui Medicine Details
- 2.3.2 Jiangsu Hengrui Medicine Major Business
- 2.3.3 Jiangsu Hengrui Medicine Anti-ANGPTL3 Antibody Lipid-lowering Drugs Product and Services
- 2.3.4 Jiangsu Hengrui Medicine Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Jiangsu Hengrui Medicine Recent Developments/Updates
- 2.4 Cspc Holdings
- 2.4.1 Cspc Holdings Details
- 2.4.2 Cspc Holdings Major Business
- 2.4.3 Cspc Holdings Anti-ANGPTL3 Antibody Lipid-lowering Drugs Product and Services
- 2.4.4 Cspc Holdings Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Cspc Holdings Recent Developments/Updates
- 2.5 Suzhou Ribo Life Science
- 2.5.1 Suzhou Ribo Life Science Details
- 2.5.2 Suzhou Ribo Life Science Major Business
- 2.5.3 Suzhou Ribo Life Science Anti-ANGPTL3 Antibody Lipid-lowering Drugs Product and Services
- 2.5.4 Suzhou Ribo Life Science Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Suzhou Ribo Life Science Recent Developments/Updates
3 Competitive Environment: Anti-ANGPTL3 Antibody Lipid-lowering Drugs by Manufacturer
- 3.1 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Revenue by Manufacturer (2021-2026)
- 3.3 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Anti-ANGPTL3 Antibody Lipid-lowering Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Manufacturer Market Share in 2025
- 3.4.3 Top 6 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Manufacturer Market Share in 2025
- 3.5 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market: Region Footprint
- 3.5.2 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market: Company Product Type Footprint
- 3.5.3 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Size by Region
- 4.1.1 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Region (2021-2032)
- 4.1.2 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Region (2021-2032)
- 4.1.3 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Average Price by Region (2021-2032)
- 4.2 North America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value (2021-2032)
- 4.3 Europe Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value (2021-2032)
- 4.4 Asia-Pacific Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value (2021-2032)
- 4.5 South America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value (2021-2032)
- 4.6 Middle East & Africa Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Type (2021-2032)
- 5.2 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Type (2021-2032)
- 5.3 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Application (2021-2032)
- 6.2 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Application (2021-2032)
- 6.3 Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Average Price by Application (2021-2032)
7 North America
- 7.1 North America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Type (2021-2032)
- 7.2 North America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Application (2021-2032)
- 7.3 North America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Size by Country
- 7.3.1 North America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Country (2021-2032)
- 7.3.2 North America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Type (2021-2032)
- 8.2 Europe Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Application (2021-2032)
- 8.3 Europe Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Size by Country
- 8.3.1 Europe Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Size by Region
- 9.3.1 Asia-Pacific Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Type (2021-2032)
- 10.2 South America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Application (2021-2032)
- 10.3 South America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Size by Country
- 10.3.1 South America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Country (2021-2032)
- 10.3.2 South America Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Size by Country
- 11.3.1 Middle East & Africa Anti-ANGPTL3 Antibody Lipid-lowering Drugs Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Anti-ANGPTL3 Antibody Lipid-lowering Drugs Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Drivers
- 12.2 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market Restraints
- 12.3 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Anti-ANGPTL3 Antibody Lipid-lowering Drugs and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Anti-ANGPTL3 Antibody Lipid-lowering Drugs
- 13.3 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Typical Distributors
- 14.3 Anti-ANGPTL3 Antibody Lipid-lowering Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Anti-ANGPTL3 Antibody Lipid-lowering Drugs. Industry analysis & Market Report on Anti-ANGPTL3 Antibody Lipid-lowering Drugs is a syndicated market report, published as Global Anti-ANGPTL3 Antibody Lipid-lowering Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Anti-ANGPTL3 Antibody Lipid-lowering Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
